Share ownership Guardant Health, Inc.

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 23/01/2026 GMT			5-day change	1st Jan Change
114.75 ^USD	-2.16%		+2.33%	+12.35%

01-13	Guardant Health, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
01-12	Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates	RE

Share class: Guardant Health, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,554,612	117,918,590 ( 95.44 %)	0	95.44 %

Major shareholders: Guardant Health, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.205 %	11,908,829	9.205 %	1 216 M $
BlackRock Advisors LLC 7.974 %	10,316,870	7.974 %	1 054 M $
Baillie Gifford & Co. 3.963 %	5,127,692	3.963 %	524 M $
Invesco Advisers, Inc. 3.81 %	4,929,543	3.81 %	504 M $
Capital Research & Management Co. (International Investors) 3.625 %	4,689,241	3.625 %	479 M $
T. Rowe Price International Ltd. 3.263 %	4,221,637	3.263 %	431 M $
Deep Track Capital LP 3.211 %	4,154,086	3.211 %	424 M $
Eventide Asset Management LLC 2.567 %	3,321,338	2.567 %	339 M $
Wellington Trust Co., NA 2.511 %	3,249,085	2.511 %	332 M $
Geode Capital Management LLC 2.27 %	2,936,656	2.27 %	300 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	84.8%
Other	7.69%
Individuals	3.81%
State Street Corp.	2.15%
Sumitomo Mitsui Trust Group, Inc.	0.58%
Manulife Financial Corp.	0.49%
SEI Investments Co.	0.21%
Schweizerische Nationalbank	0.17%
Rathbones Group Plc	0.16%
Banque Cantonale Vaudoise	0.01%
Governments	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	77.3%
United Kingdom	12.55%
Individuals	3.81%
Canada	1.1%
Norway	0.97%
Singapore	0.82%
Japan	0.72%
Austria	0.56%
France	0.5%
Germany	0.47%
Czech Republic	0.36%
Luxembourg	0.31%
Switzerland	0.22%
United Arab Emirates	0.09%
Hong Kong	0.06%
Sweden	0.06%
Denmark	0.05%
Netherlands	0.04%
Puerto Rico	0.02%
China	0.02%
Ireland	0.02%
Poland	0.01%
Italy	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,010

Sector

Medical Equipment, Supplies & Distribution

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company